UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer

Reported 1 day ago

Writing summary...

You may also interested in these wikis

South Korea Requests Extension to US Trade Deadline Amid Tariff Concerns

Soybeans Prices Dip After Long Weekend

JPMorgan Cuts Price Target on Copart (CPRT) While Maintaining Neutral Rating

Wells Fargo Reaffirms Buy Rating on Thermo Fisher Scientific

Is SoFi Technologies a Stock Worth a Fortune?

The Real Risk of Recession in the US Economy

Wells Fargo Reaffirms Buy Rating for Elevance Health (ELV) with $478 Price Target

LifeSci Capital Reiterates Buy Rating for Immunovant (IMVT) with $50 Price Target

Back to all Wikis